Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming ...
In the last year, many Amgen Inc. (NASDAQ:AMGN) insiders sold a substantial stake in the company which may have sparked ...
Amgen Inc. stock has reached a new 52-week high, hitting $345.95, marking a significant milestone for the biotechnology company. The stock is now trading just 0.99% from its 52-week high of $345.84.
Amgen Inc. (NASDAQ:AMGN) is included among the 15 Blue Chip Dividend Stocks to Build a Passive Income Porfolio. On December 3 ...
Zacks Investment Research on MSN
Here is what to know beyond why Amgen Inc. (AMGN) is a trending stock
Amgen (AMGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...
Amgen’s AMGN stock has risen almost 16% in a month. A lot of this price increase is due to strong third-quarter 2025 results, wherein both the top and bottom lines exceeded expectations. Amgen also ...
Amgen secures FDA approval for Uplinza in generalized myasthenia gravis, giving antibody-positive adults a targeted treatment option supported by Phase 3 data.
According to Benzinga Pro, Amgen Inc's peer group average for short interest as a percentage of float is 6.86%, which means the company has less short interest than most of its peers. Did you know ...
Amgen Inc. (NASDAQ:AMGN) ranks among the Best Low Volatility Investments in December 2025. Goldman Sachs reaffirmed its $400 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback